Fecha actual 07 Abr 2020 06:21

Todos los horarios son UTC + 2 horas




Nuevo tema Responder al tema  [ 1 mensaje ] 
Autor Mensaje
NotaPublicado: 16 Feb 2020 06:13 
Desconectado

Registrado: 25 Nov 2019 06:24
Mensajes: 71
Migraines are the second leading cause of disability worldwide, with more than 30 million adults affected. They can be painful, incapacitating and can last up to 72 hours without medication and often require some trial and error before finding the best treatment to control the pain.That’s why doctors and patients are excited when a new anti-migraine option is available. In this case, it's medicine called Reyvow.Reyvow is a new prescription medication that was recently approved by the Drug Enforcement Administration and is now available at pharmacies. It’s believed to act both centrally and peripherally, (which means it acts on the brain as well as on all the other nerves throughout the body). And it’s the first medication that has been shown to provide pain freedom from headaches and freedom from associated symptoms like nausea and sensitivity to light and sound."Reyvow is a new alternative treatment for acute migraines in patients not responding to medicine who have disabling problems. Having a migraine is like waiting for a hurricane to come and trying to close the windows," Dr. Peter Goadsby, Neurologist and Headache specialist at the University of California San Francisco told ABC news.The Food and Drug Administration and the DEA have approved Eli Lilly’s Reyvow (lasmiditan) as the first oral medication of its class to treat acute migraines and bothersome symptoms in adults with or without aura (visual or sensory sensations before a migraine)."We know that the migraine community is keenly interested in additional treatment options, and we remain committed to continuing to work with stakeholders to promote the development of new therapies for the acute and preventive treatment of migraine," Dr. Nick Kozauer, acting deputy director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research, said in a statement following the FDA's approval.more >>slotxo


Arriba
 Perfil  
 
Mostrar mensajes previos:  Ordenar por  
Nuevo tema Responder al tema  [ 1 mensaje ] 

Todos los horarios son UTC + 2 horas


¿Quién está conectado?

Usuarios navegando por este Foro: No hay usuarios registrados visitando el Foro y 2 invitados


No puede abrir nuevos temas en este Foro
No puede responder a temas en este Foro
No puede editar sus mensajes en este Foro
No puede borrar sus mensajes en este Foro
No puede enviar adjuntos en este Foro

Buscar:
Saltar a:  
cron